COVAXIN's efficacy is 50 percent against Coronavirus' Delta variant

The first world data of Bharat Biotech's corona vaccine has revealed that the COVAXIN has an efficacy of 50 percent against the Delta variant of Coronavirus. The details have been published in the medical journal, The Lancet. This study was done at Delhi's AIIMS Hospital. As per the researchers, the study was done when the second wave was at its peak and the case positivity was very high.